Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
A. Costantini (Boulogne Billancourt, France), C. Julie (Boulogne Billancourt, France), C. Dumenil (Boulogne Billancourt, France), Z. Hélias-Rodzewicz (Boulogne Billancourt, France), J. Dumoulin (Boulogne Billancourt, France), V. Giraud (Boulogne Billancourt, France), S. Labrune (Boulogne Billancourt, France), T. Chinet (Boulogne Billancourt, France), J. Emile (Boulogne Billancourt, France), E. Giroux-Leprieur (Boulogne Billancourt, France)
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Session: Lung cancer: new aspects in diagnosis and management
Session type: Oral Presentation
Number: 3302
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Costantini (Boulogne Billancourt, France), C. Julie (Boulogne Billancourt, France), C. Dumenil (Boulogne Billancourt, France), Z. Hélias-Rodzewicz (Boulogne Billancourt, France), J. Dumoulin (Boulogne Billancourt, France), V. Giraud (Boulogne Billancourt, France), S. Labrune (Boulogne Billancourt, France), T. Chinet (Boulogne Billancourt, France), J. Emile (Boulogne Billancourt, France), E. Giroux-Leprieur (Boulogne Billancourt, France). Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).. 3302
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: